Health & Biotech
Health & Biotech
Incannex completes landmark deal, positioning as a global leader in medicinal cannabis and psychedelics
Health & Biotech
Stock Insiders: MGC Pharmaceuticals’ ‘golden blanket’ combines multiple elements for better patient efficacy
Health & Biotech
ASX Health Stocks: Emyria takes its MDMA-inspired drugs to the next level
Health & Biotech
Bone and tissue regeneration specialist Osteopore gains access to US Federal healthcare facilities
Health & Biotech
Nutritional Growth Solutions hits new heights with South Korean expansion deal
Health & Biotech
ASX Health Stocks: Chimeric gets patent approval in Japan for CAR T assets
Health & Biotech
Incannex Engages Curia to scale-up manufacture of inhaled drug product to treat traumatic brain injury
Health & Biotech
MGC Pharma takes 40pc stake in ZAM, an AI healthcare platform that’s ‘ahead of market peers’
Health & Biotech
Leading Aussie medtechs Osteopore and Singular Health reveal landmark deal
Health & Biotech
Dr Boreham’s Crucible: Are palatable poo tests in Australia about to finally hit their Rhythm?
Health & Biotech
ScoPo’s Powerplays: Strong quarterly results boost confidence for shareholders
Health & Biotech
Onwards and upwards for Osteopore as record growth builds momentum
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.